Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

D-galactosamine lethality model: scope and limitations.

Richard Silverstein1

  • 1Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, Kansas 66160-7421, USA. rsilvers@kumc.edu

Journal of Endotoxin Research
|June 17, 2004
PubMed
Summary

D-Galactosamine (D-galN) sensitizes animals to tumor necrosis factor (TNF) lethality. This model is crucial for understanding protection mechanisms against TNF and endotoxin challenges, aiding in drug development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential modulation of the induction of inflammatory mediators by antibiotics in mouse macrophages in response to viable Gram-positive and Gram-negative bacteria.

Journal of endotoxin research·2003
Same author

Endogenous versus exogenous glucocorticoid responses to experimental bacterial sepsis.

Journal of leukocyte biology·2003
Same author

Anomalous role of tumor necrosis factor alpha in experimental enterococcal infection.

Infection and immunity·2002
See all related articles

Area of Science:

  • Immunology
  • Toxicology
  • Pharmacology

Background:

  • D-Galactosamine (D-galN) is a known sensitizer to the lethal effects of tumor necrosis factor (TNF).
  • This sensitization significantly enhances the toxicity of TNF, making it a critical factor in studying inflammatory responses.
  • TNF can be released from various immune cells like macrophages and T-cells.

Purpose of the Study:

  • To explore the D-galactosamine (D-galN) lethality model for understanding TNF-induced toxicity.
  • To investigate the protective mechanisms against TNF and lipopolysaccharide (LPS) challenges.
  • To evaluate the efficacy of different therapeutic agents in mitigating D-galN/TNF-induced lethality.

Main Methods:

  • Utilizing the D-galactosamine (D-galN) sensitization model in animals.

Related Experiment Videos

  • Challenging animals with various agents that induce TNF release, including endotoxin (LPS), superantigens, and bacterial components.
  • Assessing protection conferred by neutralizing anti-TNF antibodies, uridine, and other potential therapeutic agents.
  • Investigating differential protection patterns, such as dexamethasone's effect on LPS but not TNF challenge.

    • Main Results:

    • D-galactosamine (D-galN) dramatically increases sensitivity to TNF, requiring only small amounts of TNF to be lethal.
    • Complete protection is achieved with anti-TNF neutralizing antibodies and metabolically-based uridine.
    • Over 70 agents have shown protective effects against LPS and/or TNF challenge in this model.
    • Dexamethasone protects against LPS challenge but not direct TNF challenge, indicating distinct protective pathways.

    Conclusions:

    • The D-galactosamine (D-galN) model is a powerful tool for studying TNF-induced lethality and developing countermeasures.
    • Understanding differential protection mechanisms is key to developing targeted therapies for sepsis and inflammatory conditions.
    • The model facilitates research into synergistic effects of bacterial components and challenges with limited agent availability.